Skip to main content
S 4867 116th Congress Senate Health Advisory bodies Congressional oversight Drug safety, medical device, and laboratory regulation Drug therapy Government information and archives Health care coverage and access Health care quality Health information and medical records Health programs administration and funding Health promotion and preventive care Medical research Medical tests and diagnostic methods Neurological disorders Public contracts and procurement Research administration and funding Research and development

Accelerating Access to Critical Therapies for ALS Act

Introduced: October 26, 2020 Introduced by: Coons, Christopher A. Democratic · Delaware See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 26, 2020
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Oct 26, 2020
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Accelerating Access to Critical Therapies for ALS Act

This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions.

The Department of Health and Human Services (HHS) shall award grants to eligible entities to support research on and facilitate access to investigational drugs that diagnose or treat ALS. The Food and Drug Administration shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other severely debilitating neurodegenerative diseases.

HHS shall also establish the Collaborative for Neurodegenerative Diseases, which shall support the development and regulatory approval of drugs that address ALS and other rare neurodegenerative diseases.

What's happening now October 26, 2020

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Related & companion bills 1
  • HR 8662 Identical bill Accelerating Access to Critical Therapies for ALS Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 9
All 9 Democratic 2 Republican 6 Independent 1
R
Moran, Jerry
Kansas · Dec 30, 2020
 R
Hoeven, John
North Dakota · Dec 21, 2020
 R
Cramer, Kevin
North Dakota · Dec 16, 2020
 D
Gillibrand, Kirsten E.
New York · Dec 10, 2020
 R
Capito, Shelley Moore
West Virginia · Dec 3, 2020
 I
King, Angus S., Jr.
Maine · Dec 3, 2020
 R
Boozman, John
Arkansas · Nov 30, 2020
 D
Shaheen, Jeanne
New Hampshire · Nov 30, 2020
 R
Murkowski, Lisa
Alaska · Oct 26, 2020
Cite this page click to expand
APA
U.S. Congress. (2026). S. 4867: Accelerating Access to Critical Therapies for ALS Act. 116th Congress. Open America. https://openamerica.io/bill/116-S-4867/
MLA
"S. 4867: Accelerating Access to Critical Therapies for ALS Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-4867/.
Bluebook (legal)
S. 4867, 116th Cong. (2026), https://openamerica.io/bill/116-S-4867/.
Markdown link
[S. 4867: Accelerating Access to Critical Therapies for ALS Act](https://openamerica.io/bill/116-S-4867/)
Report a problem